Endo Reports Fourth-Quarter And Full-Year 2019 Financial Results

Go back to Endo Reports Fourth-Quarter And Full-Year 2019 Financial Results

Endo International plc (ENDP) PT Raised to $5 at Cowen

February 26, 2020 12:45 PM EST

Cowen analyst Ken Cacciatore raised the price target on Endo International plc (NASDAQ: ENDP) to $5.00 (from $4.00) while maintaining a Market Perform rating.

The analyst commented, "We maintain our thesis and would find better alternatives. The current leverage combined with the still undefined opioid... More

Endo International (ENDP) Tops Q4 EPS by 17c, Revenues Beat; Provides FY20 EPS/Revenue Outlook

February 26, 2020 6:06 AM EST

Endo International (NASDAQ: ENDP) reported Q4 EPS of $0.74, $0.17 better than the analyst estimate of $0.57. Revenue for the quarter came in at $764.8 million versus the consensus estimate of $731.43 million.

Total revenues during the fourth quarter of 2019 were $765 million, a decrease of 3% compared to fourth-quarter 2018 revenues of $786 million.Revenues of the Specialty Products portfolio of Branded Pharmaceuticals segment increased 15% in the fourth quarter of 2019 to $149 million compared to fourth-quarter 2018 revenues of $130 million.Revenues of the Sterile Injectables segment increased 10% in the fourth quarter of 2019 to $285 million compared to fourth-quarter 2018 revenues of $259... More